

DAFTAR PUSTAKA

1. Timothy J, Ali IM. Malignant pleural effusions. *Pakistan Journal of Chest Medicine* 2012;18(1): 13-22.
2. Lee Y, Light RW. Management of malignant pleural effusions. *Respirology*. 2004; 9:148-156.
3. Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Malignant pleural effusion and algorithm management. *J Thotac Dis* 2013; 5:S413-S419.
4. Sears D, Hajdu SI. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. *Acta Cytol*. 1987; 31: 85–97.
5. Neragi S, Miandoab. Malignant pleural effusion, current and evolving approaches for its diagnosis an management. *Lung Cancer*. 2006; 54 : 1-9.
6. Ngurah Rai IB. Efusi pleura maligna: diagnosis dan penatalaksanaan terkini. *J Peny Dalam*. 2009;10:208-217.
7. Rodriguez-Panadero F, Antony VB. Pleurodesis: state of the art. *Eur Respir J*. 1997;10:1648-1654.
8. Heffner JE, Paul JN, and Celia B. Pleural fluid PH as a predictor of pleurodesis failure. *Chest* 2000;117;87-95.
9. Heffner JE, Paul JN, and Celia B. Pleural fluid PH as predictor of survival for patients with malignant pleural effusions. *Chest* 2000;117;79-86..
10. Sahn SA. Pleural fluid ph in the normal state and in disease affecting the pleural space. In: Chretien J, Bignon J, Hirsch A (eds). *The pleura in health and disease*. New York: Marcel Dekker, 1985:253-66.
11. Steven AS, John E Heffner. Pleural fluid analysis. In: Light R, Lee GY, eds. *Textbook of Pleural Effusions Disease*. London: Hodder Arnold. 2008; 209-26.
12. Rodriguez-Panadero F, Ana Montes-Worboys. Mechanisms of pleurodesis. *Eur Respiration* 2012;83:91-98.
13. Thomas J, Musani A. Malignant pleural effusions a review. *Clin Chest Med* 2013;34:459-471.
14. Globokan, Cancer incidence, mortality, and prevalence worldwide. Lyon. France: International Agency for Research on Cancer Base. 2004: h 2-3.

15. Alsagaff H. Kanker Paru dalam PKB VII Ilmu Penyakit Paru; editor Wibisono M, Helmia, Margono. 2006: h 1-4.
16. Miserocchi G. Physiology and pathophysiology of pleural fluid turnover. *Eur Respir J*. 1997;10:219–25.
17. Jason A, Lonny Y, David F. The evaluation and clinical application of pleural physiologi. *Clin Chest Med*. 2013;34:11-19.
18. Hariadi S. Efusi Pleura dalam Buku Ajar Ilmu Penyakit Paru. Departemen Ilmu Penyakit Paru FK Unair - RSUD Dr. Soetomo. 2010: h 111-121.
19. Miserocchi G, Venturoli D, Negrini D, et al. Intrapleural fluid movements described by a porous flow model. *J Appl Physiol*. 1992; 73 : 2511–6.
20. Temmasonge R. Efusi Pleura Ganas dalam Diagnosis dan Tatalaksana Kegawatdaruratan Paru Dalam Praktek Sehari-hari; editor Alvin K, Agus DS, Temmasonge R, Tintin M . Sagung Seto Jakarta. 2008: h 55-67.
21. Perhimpunan Dokter Paru Indonesia dalam Kanker Paru jenis karsinoma bukan sel kecil. Balai penerbit FKUI. Jakarta. 2006. h 19-29.
22. Marhana IA. Update on Malignant pleural effusion dalam PKB XIV Ilmu Penyakit Paru. *Majalah Kedokteran Respirasi*. 2013;4: h 27-36.
23. Rodriguez-Panadero F. Effusions from malignancy. In: Light R, Lee GY, eds. *Textbook of Pleural Effusions Disease*. London: Hodder Arnold. 2008; 323-33.
24. Helm E, Martin T. Imaging of the Pleura. *Journal of Magnetic Resonance Imaging*. 2010; 32:1275–1286.
25. Heffner JE. Diagnosis and management of malignant pleural effusions. *Respirology*. 2008; 13: 5–20.
26. Abouzgheib W, Bartter T, Dagher H, Pratter M, Klump W. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. *Chest* 2009;135(4):999-1001.
27. Kouritas C. Hatzogiou, C.N. Foroulis. Low glucose level and low ph alter the electrochemical function of human parietal pleura. *Eur Respir J* 2007; 30: 354-357.
28. Gary L, Kohn MD, William D. Measuring pleural fluid pH. *Chest* 2000;118:1626-1629.

29. Antony VB, Rothfuss KJ, Godbey SW, et al. Mechanism of tetracycline-hydrochloride-induced pleurodesis. *Am Rev Respir Dis.* 1992; 146 : 1009–13.
30. Zulkifli A, Ina Ariani K. Indikasi dan Prosedur pleurodesis. *Maj Kedokt Indon*, Volum: 57, Nomor: 4, April 2007; 129-133.
31. Agarwal R, Abinash S. A randomized controlled trial of the efficacy of cosmetic talc compared with iodopovidone for chemical pleurodesis. *Respirology.* 2011;16:1064-1069.
32. Barus FA, Hudoyo A, Swidarmoko, Jusuf A. Perbandingan keberhasilan pleurodesis povidon iodine dengan doksisisiklin pada efusi pleura ganas. *J Respir Indo.*2006;26(2):69-89.
33. Perhimpunan Dokter Paru Indonesia dalam Kanker Paru jenis karsinoma bukan sel kecil. Balai penerbit FKUI. Jakarta. 2011. h 3-6.
34. Sherif Alsayed, Samar Marzouk, Sherif Abelhalim, et al. Malignant pleural effusion biomarkers as predictor for chemical pleurodesis success. *Egyptian Journal of Chest Disease and Tuberculosis* 2015. Available at <http://dx.doi.org/10.1016/j.ejcdt.2014.08.005>.
35. Ioannis P, Theodoros X, Ioannis V, et al. Pleural fluid glucose: a predictor of unsuccessful pleurodesis in a preselected cohort of patients with malignant pleural effusion. *JBUON* 2014;19(4):1018-1023.
36. Dicky S, Wiendo S, Fathiyah I. Pleurodesis pada efusi pleura ganas. *J Respir Indo.*2014;34:218-28.
37. Samah Shehata, Ashraf Sileem, Kareem El-Fakharany. Pleural fluid crp, ldh, and pH as predictors of successful pleurodesis in malignant pleural effusions. *Egyptian Journal of Chest Disease and Tuberculosis* 2015. Available at <http://dx.doi.org/10.1016/j.ejcdt.2015.05.003>.
38. Bielsa S, Hernandez P, Rodriguez-Panadero F, et al. Tumor type influences the effectiveness of pleurodesis in malignant effusions. *Lung* 2011;189:151-155.
39. Aelony Y, King RR, Boutin C. Thoracoscopic talc poudrage in malignant pleural effusions. *Chest.*1998;113:1007-12.
40. Martinez E, Aparico J, Sanchis J, et al. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. *Respiration* 1998;65(2):108-13.